Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells

Journal of Psychiatric Research
Britta StapelKai G Kahl

Abstract

Schizophrenia and major depression are associated with alterations in peripheral inflammatory markers, and anti-inflammatory therapy has been proposed as a promising add-on approach in the pharmacologic treatment of both disorders. Second-generation atypical antipsychotics are currently first-line drugs in the treatment of schizophrenia and are also used as augmentation strategies in treatment-resistant major depression. Furthermore, these drugs have been reported to exhibit distinct metabolic side effects and to influence inflammatory processes. In this study, we used ex vivo stimulation of primary human peripheral blood mononuclear cells (PBMC) from healthy blood donors with atypical antipsychotics olanzapine or aripiprazole to examine effects on cytokine production independent from metabolic side effects and disease status. Both olanzapine and aripiprazole stimulation decreased mRNA levels of IL-1β, IL-6, and TNF-α and resulted in diminished protein concentrations of IL-6 and TNF-α in conditioned medium of stimulated PBMC. A multiplex approach revealed additional downregulation of IL-2; MIP-1β and IP-10 secretion. Similarly, olanzapine and aripiprazole stimulation of the human monocytic cell line THP-1 resulted in a signific...Continue Reading

References

Feb 1, 1989·British Journal of Rheumatology·M L JenkinsonD L Scott
Aug 1, 1980·International Journal of Cancer. Journal International Du Cancer·S TsuchiyaK Tada
Feb 13, 2001·Journal of Psychiatric Research·T PollmächerD Hinze-Selch
Apr 12, 2001·Journal of Clinical Epidemiology·R Bender, S Lange
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jun 4, 2002·The American Journal of Psychiatry·Norbert MüllerMarkus J Schwarz
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mustafa BiliciMetin Ulgen
Oct 25, 2003·Psychoneuroendocrinology·Kai G KahlMartin H Schmidt
Nov 19, 2004·European Archives of Psychiatry and Clinical Neuroscience·Norbert MüllerRolf R Engel
Jun 15, 2005·Biological Psychiatry·Mark Hyman RapaportDouglas Dolnak
May 28, 2008·European Psychiatry : the Journal of the Association of European Psychiatrists·H HimmerichT Pollmächer
Sep 11, 2008·Current Drug Metabolism·G NeurauterD Fuchs
Dec 9, 2008·Biological Psychiatry·Xue-Qin SongJing-Ping Zhao
Feb 4, 2009·Psychosomatic Medicine·M Bryant HowrenJerry Suls
Jul 14, 2009·Psychoneuroendocrinology·Soili M LehtoJukka Hintikka
Aug 19, 2009·The American Journal of Psychiatry·J Craig Nelson, George I Papakostas
Sep 26, 2009·Seminars in Immunopathology·Britta Engelhardt, Lydia Sorokin
Dec 17, 2009·PM & R : the Journal of Injury, Function, and Rehabilitation·Kristin L Sainani
Dec 18, 2009·Biological Psychiatry·Yekta DowlatiKrista L Lanctôt
Aug 14, 2010·Mediators of Inflammation·Rosário Monteiro, Isabel Azevedo
Sep 10, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Chong-Bin ZhuWilliam A Hewlett
Sep 15, 2010·Current Opinion in Psychiatry·Thomas J Raedler
May 20, 2011·Journal of Psychiatric Research·Hubertus HimmerichUlrich Sack
Jun 7, 2011·Biological Psychiatry·Brian J MillerBrian Kirkpatrick
Dec 24, 2011·The American Journal of Psychiatry·Michael E BenrosPreben B Mortensen
Sep 15, 2012·Journal of Psychiatric Research·Milica BorovcaninMiodrag L Lukic
Mar 8, 2013·Depression and Anxiety·Andrew H MillerJennifer C Felger
Jan 28, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Md Mamun Al-AminHasan Mahmud Reza
Jul 16, 2014·Biochemical and Biophysical Research Communications·Anitta K SárváriZoltán Balajthy
Feb 28, 2015·Psychotherapy and Psychosomatics·Markus DoldSiegfried Kasper
May 28, 2015·The International Journal of Neuropsychopharmacology·Xinyu ZhouPeng Xie
Oct 18, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Nevena TodorovićDragana Filipović
Nov 7, 2015·Innate Immunity·Caroline Faour-Nmarne, Abed N Azab

❮ Previous
Next ❯

Citations

Jan 30, 2019·PloS One·Marcelo Soares FernandesIvana Beatrice Mânica da Cruz
Dec 4, 2019·The European Journal of Neuroscience·Caroline NothdurfterThomas C Baghai
May 30, 2019·Psychopharmacology·Robyn P ThomChristopher J McDougle
Jul 3, 2020·Journal of Child and Adolescent Psychopharmacology·Timothy R Rice, Andreas Walther
May 7, 2020·Frontiers in Endocrinology·Samantha Alvarez-HerreraLenin Pavón
May 31, 2020·Jornal de pediatria·Ann M NeumeyerChristopher J McDougle
Nov 16, 2020·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M IoannouR A Schoevers
Dec 22, 2020·Focus : Journal of Life Long Learning in Psychiatry·Giovanni OstuzziCorrado Barbui
Jan 30, 2021·Journal of Psychiatric Research·Margo ThienemannJennifer Frankovich
Feb 7, 2021·The Lancet. Psychiatry·Victor MazereelMarc De Hert
Jan 12, 2021·Frontiers in Psychiatry·Nemanja N MuricMilica M Borovcanin
Aug 8, 2021·International Journal of Molecular Sciences·Anna TkachevPhilipp Khaitovich
Dec 4, 2021·Frontiers in Cellular and Infection Microbiology·Yuying ChenJunhong Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here